Rational Design, Synthesis, Molecular Modeling and Evaluation of Β

Total Page:16

File Type:pdf, Size:1020Kb

Rational Design, Synthesis, Molecular Modeling and Evaluation of Β Facultés Universitaires Notre-Dame de la Paix Rational design, synthesis, molecular modeling and evaluation of -carboline and 5H-indeno[1,2-c]pyridazin-5-one derivatives as potential MAO and IDO inhibitors Faculté des Sciences DÉPARTEMENT DE CHIMIE Dissertation présentée par Jérémy RENIERS en vue de l’obtention du grade de Docteur en Sciences Octobre 2011 FUNDP Faculté des Sciences Département de Chimie Rational design, synthesis, molecular modeling and evaluation of -carboline and 5H-indeno[1,2-c]pyridazin-5-one derivatives as potential MAO and IDO inhibitors Dissertation présentée par Jérémy RENIERS en vue de l’obtention du grade de Docteur en Sciences Composition du jury : Prof. S. Vincent (FUNDP, Namur, président du jury) Prof. R. Kiss (ULB, Bruxelles) Prof. C. Michiels (FUNDP, Namur) Dr. R. Frédérick (FUNDP, Namur) Prof. J. Wouters (FUNDP, Namur, promoteur) 2011 © Presses universitaires de Namur & Jérémy Reniers Rempart de la Vierge, 13 B - 5000 Namur (Belgique) Toute reproduction d'un extrait quelconque de ce livre, hors des limites restrictives prévues par la loi, par quelque procédé que ce soit, et notamment par photocopie ou scanner, est strictement interdite pour tous pays. Imprimé en Belgique ISBN : 978-2-87037 -734-5 Dépôt légal: D / 2011 / 1881 / 39 Facultés Universitaires Notre-Dame de la Paix Faculté des Sciences Rue de Bruxelles 61 - 5000 Namur, Belgique Conception rationnelle, synthèse, modélisation moléculaire et évaluation de dérivés - carbolines et 5H-indéno[1,2-c]pyridazin-5-ones comme inhibiteurs potentiels de la MAO et d’IDO Par Jérémy Reniers Résumé: La monoamine oxydase A (MAO-A) et –B (MAO-B) sont des cibles intéressantes pour une large gamme de thérapies contre des pathologies telles que la dépression, l’anxiété et les maladies de Parkinson et d’Alzheimer. La plupart des inhibiteurs actuels mènent à des effets secondaires par un manque d’affinité et de sélectivité envers une des isoformes. Récemment, les structures cristallographiques de hMAO-A et –B en complexe avec des inhibiteurs ont ouvert le chemin vers la découverte de nouveaux inhibiteurs plus sélectifs et plus puissants. En conséquence, l’objectif principal de ce travail, fut la conception de nouveaux inhibiteurs plus puissants, réversibles et sélectifs de MAO-A ou –B à partir des motifs β-carbolines et 5H-indéno[1,2-c]pyridazin-5-ones respectivement, en suivant une stratégie classique comprenant une approche expérimentale (synthèse et évaluation biologique) et théorique (modélisation moléculaire). Les pouvoirs d’inhibition sur la MAO ont montré que la substitution du groupe méthoxy de l’harmine par des groupes plus lipophiles augmente l’inhibition de MAO-A. Des études sur les 5H-indéno[1,2-c]pyridazin-5- ones substituées à la fois aux positions 3 et 8 par des groupes lipophiles ont montré que la substitution en position 3 influence significativement les propriétés d’inhibition de la MAO- B. De plus, l’implication à travers une même voie métabolique et la similarité dans les propriétés structurales de la MAO avec l’indoléamine 2,3-dioxygénase (IDO) et la lysine spécifique déméthylase 1 (LSD1) respectivement, nous ont amené à l’investigation des -carbolines et 5H-indéno[1,2-c]pyridazin-5-ones comme inhibiteurs potentiels d’IDO et de LSD1. Cependant, les deux series n’inhibent pas ces deux systèmes enzymatiques et sont donc sélectives de MAO. Finalement, en partant de la même stratégie utilisée pour la MAO, nous nous sommes aussi intéressés à la synthèse de deux nouvelles -carbolines substitutées en position 3 par des groupements aminés et directement dérivées du 3-butyl--carboline, un inhibiteur connu d’IDO. Ces deux composés présentent en effet une charge positive à pH physiologique laquelle pourrait établir une interaction coulombienne supplémentaire avec le 7-propionate de l’hème comparé au 3-butyl--carboline. Cependant, les premiers résultats tendent à démontrer que l’introduction d’une charge positive abolit l’inhibition d’IDO. Dissertation doctorale en Sciences 4 octobre 2011 Laboratoire de Chimie Biologique Structurale (Prof. J. Wouters) Promoteur: Prof. J. Wouters Facultés Universitaires Notre-Dame de la Paix Faculté des Sciences Rue de Bruxelles 61 - 5000 Namur, Belgium Rational design, synthesis, molecular modeling and evaluation of -carboline and 5H-indeno[1,2-c]pyridazin-5-one derivatives as potential MAO and IDO inhibitors By Jérémy Reniers Abstract: Monoamine oxidase A (MAO-A) and –B (MAO-B) are attractive targets for a broad range of treatments against pathologies including depression, anxiety disorders, Parkinson’s and Alzheimer’s diseases. Most current MAO inhibitors lead to side effects by a lack of affinity and selectivity towards one of the isoforms. Recently, the crystal structures of hMAO- A and –B in complex with inhibitors opened the way towards the discovery of new, more selective and potent inhibitors. Thus, the main objective of this work, was the design of new, more potent, reversible and selective MAO-A or –B inhibitors derived from β-carboline and 5H-indeno[1,2-c]pyridazin-5-one scaffolds respectively, following a classical strategy including experimental (synthesis and biological evaluation) and theoretical (molecular modeling) approaches. The MAO inhibitory potencies showed that the replacement of the methoxy group of harmine by more lipophilic groups increases the inhibition for MAO-A. Studies on 5H-indeno[1,2-c]pyridazin-5-one scaffold bearing lipophilic groups in the 3 and 8- positions showed that the substitution in the 3-position dramatically influences the MAO-B- inhibiting properties. Furthermore, the involvement through a same metabolic pathway and the similarity in the structural properties of MAO with indoleamine 2,3-dioxygenase (IDO) and lysine specific demethylase 1 (LSD1) respectively, led us to the investigation of the -carboline and 5H- indeno[1,2-c]pyridazin-5-one derivatives as potential IDO and LSD1 inhibitors. However, the two series show no inhibition of those two enzymes and are thus selective of MAO. Finally, starting from the same strategy used for MAO, we are also interested in the synthesis of two new 3-substituted--carboline derivatives with amino groups and directly derived from 3-butyl--carboline, a known IDO inhibitor. Indeed, these two compounds display a positive charge at physiological pH which might establish an additional coulomb interaction with 7- propionate of the heme compared to 3-butyl--carboline. Howerver, first results tend to demonstrate that the introduction of a positive charge abolishes the inhibition of IDO. Ph.D. thesis in Sciences October 4, 2011 Laboratoire de Chimie Biologique Structurale (Prof. J. Wouters) Advisor: Prof. J. Wouters Au terme de ces quatre années de thèse passées au sein du laboratoire de Chimie Biologique Structurale, je tiens à exprimer mes remerciements les plus sincères à toutes les personnes qui ont contribué, de près ou de loin, par leur aide et/ou leur soutien, à l'élaboration de ce travail, parmi eux : - Tout d’abord, je voudrais remercier le Professeur Johan Wouters pour m’avoir accueilli dans son laboratoire. Je tiens aussi à le remercier pour ses conseils judicieux et pour son attention lesquels m’ont permis d’acquérir de l’expérience et d’enrichir mes connaissances tout au long de ces quatre années. Finalement, un immense merci pour toute la confiance qu’il m’a accordée ainsi que pour m’avoir donné la chance d’explorer ma thèse à travers différents domaines de la chimie. - Je tiens à exprimer toute ma gratitude au Professeur Stéphane Vincent pour l’expérience de la chimie des sucres et de la chimie organique qu’il m’a enseignée au cours de mon mémoire laquelle m’a permis de développer une rigueur dans ma démarche scientifique et d’acquérir une autonomie. Celles-ci ont été très importantes pour ma thèse et je le remercie aussi pour m’avoir permis d’utiliser ses installations et matériels au cours de ces années. - Je remercie le Professeur Bernard Masereel du Département de Pharmacie pour m’avoir permis d’utiliser ses installations et matériels au cours de ces quatre années. - Je suis tout particulièrement reconnaissant à Séverine Robert pour l’aide qu’elle m’a fournie pour la mise au point du test enzymatique sur les monoamines oxydases. - Je tiens ensuite à adresser mes remerciements à tous les chercheurs du laboratoire CBS et du CBO pour leur bonne humeur ainsi que pour leurs conseils tout au long de la réalisation de cette thèse. - Je remercie Bernadette Norberg pour l’aide qu’elle m’a apportée afin de me former à la résolution de structures cristallines. - Je remercie Anne-Marie Murray pour les analyses élémentaires. - Je remercie aussi Benoit Georges pour toute sa sympathie et ses conseils précieux. - Un tout grand merci aux informaticiens Laurent et Fréderick pour leur gentillesse et leur aide. - Je remercie les Facultés Universitaires Notre-Dame de la Paix ainsi que le FNRS qui m’ont apporté leur soutien financier. - Je suis reconnaissant aux membres de mon jury d’avoir accepté d’en faire partie. - Je tiens aussi à remercier tous les stagiaires (Jérémy Maury et Christelle Vancrayenest) et mémorants (Sylvain Arcidiacono et Céline Meinguet) que j’ai eu la chance d’encadrer au cours de ma thèse pour le sérieux et la qualité du travail qu’ils ont réalisé. - Enfin, je désire exprimer toute ma reconnaissance à mes parents, ma sœur Anne- Sophie, ma compagne Marion et à tous mes amis qui se reconnaitront pour leur soutien, leur patience et toute leur bonne humeur pendant les moments difficiles que j’ai pu avoir. " Ne jamais conclure
Recommended publications
  • Designing Inhibitors Via Molecular Modelling Methods for Monoamine Oxidase Isozymes a and B Filiz Varnali Kadir Has Universit
    DESIGNING INHIBITORS VIA MOLECULAR MODELLING METHODS FOR MONOAMINE OXIDASE ISOZYMES A AND B FİLİZ VARNALI KADİR HAS UNIVERSITY 2012 DESIGNING INHIBITORS VIA MOLECULAR MODELLING METHODS FOR MONOAMINE OXIDASE ISOZYMES A AND B FİLİZ VARNALI M.S. in Computational Biology and Bioinformatics, Kadir Has University, 2012 Submitted to the Graduate School of Science and Engineering in partial fulfilment of the requirements for the degree of Master of Science in Computational Biology and Bioinformatics KADİR HAS UNIVERSITY 2012 DESIGNING INHIBITORS VIA MOLECULAR MODELING METHODS FOR MONOAMINE OXIDASE ISOZYMES A AND B Abstract In drug development studies, a large number of new drug candidates (leads) have to be synthesized and optimized by changing several moieties of the leads in order to increase efficacies and decrease toxicities. Each synthesis of these new drug candidates include multi-steps procedures. Overall, discovering a new drug is a very time-consuming and very costly works. The development of molecular modelling programs and their applications in pharmaceutical research have been formalized as a field of study known computer assisted drug design (CADD) or computer assisted molecular design (CAMD). In this study, using the above techniques, Monoamine Oxidase isozymes, which play an essential role in the oxidative deamination of the biogenic amines, were studied. Compounds that inhibit these isozymes were shown to have therapeutic value in a variety of conditions including several psychiatric and neurological as well as neurodegenerative diseases. First, a series of new pyrazoline derivatives were screened using molecular modelling and docking methods and promising lead compounds were selected, and proposed for synthesis as novel selective MAO-A or –B inhibitors.
    [Show full text]
  • Treatment of Social Phobia with Antidepressants
    Antidepressants for Social Phobia Treatment of Social Phobia With Antidepressants Franklin R. Schneier, M.D. This article reviews evidence for the utility of antidepressant medications in the treatment of social phobia. Monoamine oxidase inhibitors (MAOIs) were the first antidepressants shown to be effective © Copyrightfor social phobia, but 2001dietary restrictions Physicians and a relatively Postgraduate high rate of adverse effects Press, often relegate Inc. MAOIs to use after other treatments have been found ineffective. Reversible inhibitors of monoamine oxidase (RIMAs) hold promise as safer alternatives to MAOIs, but RIMAs may be less effective and are currently unavailable in the United States. Selective serotonin reuptake inhibitors (SSRIs), of which paroxetine has been the best studied in social phobia to date, have recently emerged as a first- line treatment for the generalized subtype of social phobia. The SSRIs are well tolerated and consis- tently have been shown to be efficacious in controlled trials. (J Clin Psychiatry 2001;62[suppl 1]:43–48) arly evidence that antidepressantsOne might personal have utility copy maypressant be printed treatment of other anxiety disorders, such as panic E in the treatment of social phobia emerged in the disorder and obsessive-compulsive disorder. In particular, 1970s when studies found efficacy for monoamine oxidase the high rate of comorbidity of anxiety disorders with de- inhibitors (MAOIs) in patient samples that included both pression3 makes treatment with antidepressants an efficient
    [Show full text]
  • Insights Into the Mechanisms of Action Ofthe MAO Inhibitors Phenelzine and Tranylcypromine
    Insights into the Mechanisms of Action of the MAO Inhibitors Phenelzine and Tranylcypromine: A Review Glen B. Baker, Ph.D., Ronald T. Coutts, Ph.D., D.Sc., Kevin F. McKenna, M.D., and Rhonda L. Sherry-McKenna, B.Sc. Neurochemical Research Unit, Department of Psychiatry and Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta Submitted: July 10, 1992 Accepted: October 7, 1992 Although the non-selective monoamine oxidase inhibitors phenelzine and tranylcypromine have been used for many years, much still remains to be understood about their mechanisms of action. Other factors, in addition to the inhibition of monoamine oxidase and the subsequent elevation of brain levels of the catecholamines and 5-hydroxytryptamine, may contribute to the overall pharma- cological profiles ofthese drugs. This review also considers the effects on brain levels of amino acids and trace amines, uptake and release of neurotransmitter amines at nerve terminals, receptors for amino acids and amines, and enzymes other than monoamine oxidase, including enzymes involved in metabolism of other drugs. The possible contributions of metabolism and stereochemistry to the actions of these monoamine oxidase inhibitors are discussed. Key Words: amino acids, monoamine oxidase, neurotransmitter amines, phenelzine, tranylcypromine, uptake Despite the fact that the non-selective monoamine oxidase nerve endings (Baker et al 1977; Raiteri et al 1977) and/or (MAO) inhibitors phenelzine (PLZ) and tranylcypromine may act as neuromodulators through direct actions on recep- (TCP) (see Fig. 1) have been used clinically for many years, tors for the catecholamines and/or 5-HT (Jones 1983; much remains to be learned about theirmechanisms ofaction.
    [Show full text]
  • Official Protocol Title: NCT Number: NCT02750761
    Official Protocol Title: A Phase 1, Single-Administration Pharmacokinetic and Safety Study of Oral and IV Tedizolid Phosphate in Hospitalized Subjects 2 to <12 Years Old NCT number: NCT02750761 Document Date: 23-Jun-2017 Tedizolid Phosphate (MK-1986) 1 Protocol TR701-120/MK-1986-013, Amendment 4 THIS PROTOCOL AND ALL OF THE INFORMATION RELATING TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC., WHITEHOUSE STATION, NJ, U.S.A. SPONSOR: Cubist Pharmaceuticals, LLC, A wholly-owned indirect subsidiary of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (hereafter referred to as the Sponsor or Merck) Weystrasse 20, Lucerne 6 Switzerland Protocol-specific Sponsor Contact information can be found in the Investigator Trial File Binder (or equivalent). TITLE: A Phase 1, Single-Administration Pharmacokinetic and Safety Study of Oral and IV Tedizolid Phosphate in Hospitalized Subjects 2 to <12 Years Old IND NUMBER: [106,307 (IV) and 125,076 (Oral Suspension)] EudraCT NUMBER: 2015-004595-29 23-Jun-2017 Confidential 04PPD9 Tedizolid Phosphate (MK-1986) 2 Protocol TR701-120, Amendment 4 SUMMARY OF CHANGES: TR701-120 Amendment 4 PRIMARY REASON(S) FOR THIS AMENDMENT: Section Change Rationale 1.0 Synopsis Updated dose for 6 to <12 years from 5 mg/kg to The dose level for the two age groups was adjusted Methodology; 4mg/kg, dose for 2 to <6 years from 5 mg/kg to 6 based on the results of the first interim analysis of the Investigational mg/kg based on the data from interim safety and safety and pharmacokinetic data.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0011643 A1 Dilisa Et Al
    US 2015 0011643A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0011643 A1 DiLisa et al. (43) Pub. Date: Jan. 8, 2015 (54) TREATMENT OF HEART FAILURE AND (60) Provisional application No. 61/038,230, filed on Mar. ASSOCATED CONDITIONS BY 20, 2008, provisional application No. 61/155,704, ADMINISTRATION OF MONOAMINE filed on Feb. 26, 2009. OXIDASE INHIBITORS (71) Applicants:Nazareno Paolocci, Baltimore, MD Publication Classification (US); Univeristy of Padua, Padova (IT) (51) Int. Cl. (72) Inventors: Fabio DiLisa, Padova (IT): Ning Feng, A63L/38 (2006.01) Baltimore, MD (US); Nina Kaludercic, (52) U.S. Cl. Baltimore, MD (US); Nazareno CPC ..... ... A61 K31/138 (2013.01) Paolocci, Baltimore, MD (US) USPC .......................................................... S14/651 (21) Appl. No.: 14/332,234 (22) Filed: Jul. 15, 2014 (57) ABSTRACT Related U.S. Application Data Administration of monoamine oxidase inhibitors is useful in (63) Continuation of application No. 12/407,739, filed on the prevention and treatment of heart failure and incipient Mar. 19, 2009, now abandoned. heart failure. Patent Application Publication Jan. 8, 2015 Sheet 1 of 2 US 201S/0011643 A1 Figure 1 Sial 8. Sws-L) Cleaved Š Caspase-3 ) Figure . Prevention of caspase-3 productief) fron cardiomyocytes Lapoi) reatment with clorgyi Be. Patent Application Publication Jan. 8, 2015 Sheet 2 of 2 US 201S/0011643 A1 Figure 2 8:38:8 ::::::::8: US 2015/0011643 A1 Jan. 8, 2015 TREATMENT OF HEART FAILURE AND in the art is a variety of MAO inhibitors and their pharmaceu ASSOCATED CONDITIONS BY tically acceptable compositions for administration, in accor ADMINISTRATION OF MONOAMINE dance with the present invention, to mammals including, but OXIDASE INHIBITORS not limited to, humans.
    [Show full text]
  • Attendee Guidelines
    (Temple of Eternal Sound) Attendee Guidelines 1. Introduction 2. Practical Guidelines -Preparation -Contraindications -Food -Clothing -Cleansing -During the Session -Suggested Best Practices -Temple Practices & Ritual Norms -Single Sacrament Sanctuary 3. Code of Ethics 4. Dietary Guidelines 5. Medical Information 6. Attendee Waiver Céu do Som Welcome, Thank you for your interest in our Forest Family Circles, Realisation Retreats and Wisdom Works at the Temple of Céu do Som & Abuelatree Sanctuary. You are endeavouring to participate in what, for us, is one of the most profound and meaningful doorways into the mysteries of the Sacred & Profound. The following pages are practical suggestions outlining our expectations, guidelines and safety measures to ensure harmony for you, for our work and for our community. We seek to uphold a high standard in regards to the safe space of transformation and realisation that may create a positive impact through healing and integration of our participants. The guidelines in this booklet all serve a direct purpose. We ask that each one be approached with due respect. It is not necessary to subscribe to our points of view in order to receive the sacrament. We do not discriminate and find that ultimately it is up to the individual to discover what is true for them. Así Céu do Som PRACTICAL GUIDELINES Preparation for the spiritual study Contraindications (refer to Medical Information section for more details) 1. If you are uncertain about any contraindications or factors please ask. 2. If you have any personal concerns a meeting can be arranged prior in order to discuss. 3. If you are taking any prescription medication, namely antidepressants, antipsychotics or SSRI's please speak to us (Refer to Medical Information section).
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Lower Monoamine Oxidase-A Total Distribution Volume in Impulsive
    Neuropsychopharmacology (2015) 40, 2596–2603 © 2015 American College of Neuropsychopharmacology. All rights reserved 0893-133X/15 www.neuropsychopharmacology.org Lower Monoamine Oxidase-A Total Distribution Volume in Impulsive and Violent Male Offenders with Antisocial Personality Disorder and High Psychopathic Traits: An [11C] Harmine Positron Emission Tomography Study 1,2,3,4 1,2 1,2,3 1,2,3 1,2,3,5 Nathan J Kolla , Brittany Matthews , Alan A Wilson , Sylvain Houle , R Michael Bagby , 4,6 3 1,2 *,1,2,3,4 Paul Links , Alexander I Simpson , Amina Hussain and Jeffrey H Meyer 1Centre for Addiction and Mental Health (CAMH) Research Imaging Centre, Toronto, Ontario, Canada; 2Campbell Family Mental Health Research 3 4 Institute, CAMH, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada; Institute of Medical 5 6 Science, University of Toronto, Toronto, Ontario, Canada; Department of Psychology, University of Toronto, Toronto, Ontario, Canada; Department of Psychiatry, University of Western Ontario, Toronto, Ontario, Canada Antisocial personality disorder (ASPD) often presents with highly impulsive, violent behavior, and pathological changes in the orbitofrontal cortex (OFC) and ventral striatum (VS) are implicated. Several compelling reasons support a relationship between low monoamine oxidase-A (MAO-A), an enzyme that regulates neurotransmitters, and ASPD. These include MAO-A knockout models in rodents evidencing impulsive aggression and positron emission tomography (PET) studies of healthy subjects reporting associations between low brain MAO-A levels and greater impulsivity or aggression. However, a fundamental gap in the literature is that it is unknown whether brain 11 MAO-A levels are low in more severe, clinical disorders of impulsivity, such as ASPD.
    [Show full text]
  • Ssris and Tricyclic Antidepressants Increase Response Rates in Post-Traumatic Stress Disorder in the Short Term
    Evid Based Mental Health: first published as 10.1136/ebmh.4.2.54 on 1 May 2001. Downloaded from Review: SSRIs and tricyclic antidepressants increase response rates in post-traumatic stress disorder in the short term Stein DJ, Zungu-Dirwayi N, van Der Linden GJ, et al. Pharmacotherapy for posttraumatic stress disorder. Cochrane Database Syst Rev 2000;(4):CD002795 (latest version 20 Jul 2000). QUESTION: In patients with post-traumatic stress disorder (PTSD), is pharmacotherapy effective for relieving symptoms? Data sources Main results Studies were identified by searching Medline (1966–99); 13 RCTs (14 comparisons) of tricyclic antidepressants PsycLIT; the National PTSD Center Pilots database; (TCAs) (3 comparisons), monoamine oxidase Dissertation Abstracts; and the Cochrane Collaboration (MAO) inhibitors (2 comparisons), brofaromine Depression, Anxiety & Neurosis Controlled Trials Regis- (2 comparisons), selective serotonin reuptake inhibitors ter; by scanning reference lists of articles; and by contact- (SSRIs) (4 comparisons), alprazolam (1 comparison), ing researchers and pharmaceutical companies. lamotrigine (1 comparison), and inositol (1 compari- son) met criteria. Follow up ranged from 4–14 weeks Study selection (mean 9 wks). More patients responded to SSRIs Source of funding: Published or unpublished randomised controlled trials MRC Research Unit on or TCAs than placebo (table). In 1 RCT, phenelzine led Anxiety and Stress (RCTs) in any language were selected if participants had to a higher response rate than placebo; 1 small RCT Disorders, Cape Town, PTSD (as defined by authors) and if a drug was of lamotrigine and 2 RCTs of brofaromine showed no South Africa. compared with placebo or another drug. difference in response rates between groups For correspondence: Data extraction (table).
    [Show full text]
  • In Utero Exposure to Antidepressant Drugs and Risk of Attention Deficit Hyperactivity Disorder (ADHD)
    FACULTY OF HEALTH SCIENCE; AARHUS UNIVERSITY In utero exposure to antidepressant drugs and risk of attention deficit hyperactivity disorder (ADHD): A nationwide Danish cohort study Research year report Kristina Laugesen Department of Clinical Epidemiology, Aarhus University Hospital Supervisors Henrik Toft Sørensen, MD, PhD, DMSc, professor (main supervisor) Department of Clinical Epidemiology Aarhus University Hospital Denmark Morten Olsen, MD, PhD (co-supervisor) Department of Clinical Epidemiology Aarhus University Hospital Denmark Ane Birgitte Telén Andersen, PhD-student, MPH (co-supervisor) Department of Clinical Epidemiology Aarhus University Hospital Denmark Preface This study was carried out during my research year at Department of Clinical Epidemiology, Aarhus University Hospital, Denmark (February 2012 - January 2013). I would like to express my gratefulness to my main supervisor Henrik Toft Sørensen and the Department of Clinical Epidemiology. This department contributes to research of high standard and I feel lucky to have been a part of the research environment here. From my point of view a research environment of high standard originates not only from bright and innovative people but also from the ability to work together, share knowledge and ideas and make use of people´s different skills, all qualities possessed by this department. Thank you for having introduced me to epidemiological research, I have definitely been encouraged to continue research in this field. Also I would like to say thank you for giving me the possibility to go to Boston for three months during my research year. It has been an experience of great personal and intellectual gain. A special thanks to Elizabeth Hatch who have warmly welcomed us at the Department of Public Health, Boston University.
    [Show full text]
  • Mikocka-Walus Et Al-2017
    This is a repository copy of Adjuvant therapy with antidepressants for the management of inflammatory bowel disease (Protocol). White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/118724/ Version: Published Version Article: Mikocka-Walus, Antonina Anna orcid.org/0000-0003-4864-3956, Fielder, Andrea, Prady, Stephanie Louise orcid.org/0000-0002-8933-8045 et al. (3 more authors) (2017) Adjuvant therapy with antidepressants for the management of inflammatory bowel disease (Protocol). Cochrane Database of Systematic Reviews. ISSN 1469-493X https://doi.org/10.1002/14651858.CD012680 Reuse Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Cochrane Database of Systematic Reviews Adjuvant therapy with antidepressants for the management of inflammatory bowel disease (Protocol) Mikocka-Walus A, Fielder A, Prady SL, Esterman AJ, Knowles S, Andrews JM Mikocka-Walus A, Fielder A, Prady SL, Esterman AJ, Knowles S, Andrews JM. Adjuvant therapy with antidepressants for the management of inflammatory bowel disease.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]